Compare Aehr Test Systems (AEHR) vs Hims and Hers Health Inc (HIMS) Price & Performance

AEHR trades at $72.33, up 3.38% today, with a bullish technical signal driven by oversold RSI readings near 24.5, though moving averages remain bearish. The company reported Q1 2026 EPS of -$0.05, beating expectations, but maintains negative profitability margins and cash flow. Recent news highlights strong order growth from AI and silicon photonics customers, including a follow-on system order announced June 17, 2026.

Outlook is mixed: robust order book and AI sector tailwinds support growth, but high P/S of 46.6 and persistent losses pose valuation risks. Analyst consensus is cautious with 33% buy ratings. Key risks include execution on orders and cash burn.

Hims & Hers Health trades at $38.28, up 4.02% today, showing strong momentum near its 52-week high. The stock exhibits a bullish technical trend with support at $37 and resistance at $39. Fundamentally, revenue reached $2.35 billion in 2025 with a gross margin of 71.72%, though net income turned negative in 2026. Recent news highlights growth in weight-loss subscriptions and a price target increase from Canaccord Genuity to $40 (July 1, 2026).

The outlook is mixed: bullish technicals and subscriber growth contrast with high valuation multiples (P/E 57.14) and recent earnings misses. Key risks include execution in competitive telehealth and reliance on obesity drug trends. Analysts are cautious with 65% hold ratings, consensus target $33.43 suggests limited upside from current levels.